Logo image of AKBA

AKEBIA THERAPEUTICS INC (AKBA) Stock Overview

NASDAQ:AKBA - US00972D1054 - Common Stock

3.13 USD
+0.12 (+3.99%)
Last: 8/28/2025, 8:00:00 PM
3.06 USD
-0.07 (-2.24%)
Pre-Market: 8/29/2025, 4:00:00 AM

AKBA Key Statistics, Chart & Performance

Key Statistics
52 Week High4.08
52 Week Low1.24
Market Cap829.92M
Shares265.15M
Float249.92M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.17
PEN/A
Fwd PE31.47
Earnings (Next)11-05 2025-11-05/bmo
IPO03-20 2014-03-20
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


AKBA short term performance overview.The bars show the price performance of AKBA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60

AKBA long term performance overview.The bars show the price performance of AKBA in the last 1, 2 and 3 years. 1 year 2 years 3 years 200 400 600

The current stock price of AKBA is 3.13 USD. In the past month the price decreased by -15.06%. In the past year, price increased by 101.94%.

AKEBIA THERAPEUTICS INC / AKBA Daily stock chart

AKBA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.63 367.30B
AMGN AMGEN INC 13.1 153.76B
GILD GILEAD SCIENCES INC 14.54 139.67B
VRTX VERTEX PHARMACEUTICALS INC 23.14 100.52B
REGN REGENERON PHARMACEUTICALS 12.7 61.43B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.29B
ARGX ARGENX SE - ADR 75.95 43.09B
ONC BEONE MEDICINES LTD-ADR 6 35.42B
INSM INSMED INC N/A 28.53B
BNTX BIONTECH SE-ADR N/A 24.50B
NTRA NATERA INC N/A 23.04B
BIIB BIOGEN INC 8.29 19.45B

About AKBA

Company Profile

AKBA logo image Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 181 full-time employees. The company went IPO on 2014-03-20. The firm is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. The company utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Company Info

AKEBIA THERAPEUTICS INC

245 First Street

Cambridge MASSACHUSETTS 02142 US

CEO: John P. Butler

Employees: 181

AKBA Company Website

AKBA Investor Relations

Phone: 16178712098

AKEBIA THERAPEUTICS INC / AKBA FAQ

What is the stock price of AKEBIA THERAPEUTICS INC today?

The current stock price of AKBA is 3.13 USD. The price increased by 3.99% in the last trading session.


What is the ticker symbol for AKEBIA THERAPEUTICS INC stock?

The exchange symbol of AKEBIA THERAPEUTICS INC is AKBA and it is listed on the Nasdaq exchange.


On which exchange is AKBA stock listed?

AKBA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for AKEBIA THERAPEUTICS INC stock?

11 analysts have analysed AKBA and the average price target is 7.55 USD. This implies a price increase of 141.15% is expected in the next year compared to the current price of 3.13. Check the AKEBIA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is AKEBIA THERAPEUTICS INC worth?

AKEBIA THERAPEUTICS INC (AKBA) has a market capitalization of 829.92M USD. This makes AKBA a Small Cap stock.


How many employees does AKEBIA THERAPEUTICS INC have?

AKEBIA THERAPEUTICS INC (AKBA) currently has 181 employees.


What are the support and resistance levels for AKEBIA THERAPEUTICS INC (AKBA) stock?

AKEBIA THERAPEUTICS INC (AKBA) has a support level at 3.12 and a resistance level at 3.2. Check the full technical report for a detailed analysis of AKBA support and resistance levels.


Is AKEBIA THERAPEUTICS INC (AKBA) expected to grow?

The Revenue of AKEBIA THERAPEUTICS INC (AKBA) is expected to grow by 43.72% in the next year. Check the estimates tab for more information on the AKBA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy AKEBIA THERAPEUTICS INC (AKBA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does AKEBIA THERAPEUTICS INC (AKBA) stock pay dividends?

AKBA does not pay a dividend.


When does AKEBIA THERAPEUTICS INC (AKBA) report earnings?

AKEBIA THERAPEUTICS INC (AKBA) will report earnings on 2025-11-05, before the market open.


What is the Price/Earnings (PE) ratio of AKEBIA THERAPEUTICS INC (AKBA)?

AKEBIA THERAPEUTICS INC (AKBA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.17).


What is the Short Interest ratio of AKEBIA THERAPEUTICS INC (AKBA) stock?

The outstanding short interest for AKEBIA THERAPEUTICS INC (AKBA) is 10.01% of its float. Check the ownership tab for more information on the AKBA short interest.


AKBA Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to AKBA. When comparing the yearly performance of all stocks, AKBA is one of the better performing stocks in the market, outperforming 92.41% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

AKBA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to AKBA. While AKBA is still in line with the averages on profitability rating, there are concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AKBA Financial Highlights

Over the last trailing twelve months AKBA reported a non-GAAP Earnings per Share(EPS) of -0.17. The EPS increased by 19.05% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -10.56%
ROE -124.84%
Debt/Equity 1.61
Chartmill High Growth Momentum
EPS Q2Q%100%
Sales Q2Q%43.13%
EPS 1Y (TTM)19.05%
Revenue 1Y (TTM)16.79%

AKBA Forecast & Estimates

11 analysts have analysed AKBA and the average price target is 7.55 USD. This implies a price increase of 141.15% is expected in the next year compared to the current price of 3.13.

For the next year, analysts expect an EPS growth of 78.36% and a revenue growth 43.72% for AKBA


Analysts
Analysts87.27
Price Target7.55 (141.21%)
EPS Next Y78.36%
Revenue Next Year43.72%

AKBA Ownership

Ownership
Inst Owners35.93%
Ins Owners3.61%
Short Float %10.01%
Short Ratio5.56